Skip to main content
SpringerLink
Log in

Oral chemotherapy in the elderly: consideration of pharmacokinetics can optimise outcomes

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Skirvin JA, Lichtman SM. Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging 2002; 19: 25–42

    Article  PubMed  CAS  Google Scholar 

  2. Kimmick GG, Fleming R, Buss HB, Balducci L. Cancer chemotherapy in older adults. A tolerability perspective. Drugs Aging 1997; 10: 34–49

    Article  PubMed  CAS  Google Scholar 

  3. Canal P, Chatelut E, Guichard S, et al. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998; 56: 1019–38.

    Article  PubMed  CAS  Google Scholar 

  4. Mayersohn M. Special pharmacokinetic considerations in the elderly. In: Evans WE, editor. Applied pharmacokinetics: principles of therapeutic drug monitoring. 2nd ed. Vancouver: Applied Therapeutics, 1986: 244–6

    Google Scholar 

  5. Walker AH, Jaffe JM, Gunasegaram S, et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Hum Mutat Online 1998; 12: 289

    CAS  Google Scholar 

  6. Masson E, Zamboni WC. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clin Pharmacokinet 1997; 32: 324–43

    Article  PubMed  CAS  Google Scholar 

  7. Smythe M, Hoffman J, Kizy K, et al. Estimating creatinine clearance in elderly patients with low serum creatinine concentrations. Am J Hosp Pharm 1994; 51: 198–204

    PubMed  CAS  Google Scholar 

  8. Balducci L, Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer 1997; 80: 1317–22

    Article  PubMed  CAS  Google Scholar 

  9. McEvoy G. AHFS 2000: drug information. Bethesda (MD): American Society of Health System Pharmacists, 2000

    Google Scholar 

  10. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061–7

    Article  PubMed  CAS  Google Scholar 

  11. Physicians desk reference. 56th ed. Montvale (NJ): Medical Economics Company, 2002

  12. Camaggi CM, Strocchi E, Carsi P, et al. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chemother Pharmacol 1992; 30: 307–16

    Article  PubMed  CAS  Google Scholar 

  13. Iyer L, Ratain MJ. 5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest 1999; 17: 494–506

    Article  PubMed  CAS  Google Scholar 

  14. Aita P, Robieux I, Sorio R, et al. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 1999; 43: 287–94

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oral chemotherapy in the elderly: consideration of pharmacokinetics can optimise outcomes. Drugs Ther. Perspect 18, 20–23 (2002). https://doi.org/10.2165/00042310-200218110-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200218110-00007

Keywords

Search

Navigation